Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

NASDAQ:ELUT - Nasdaq - US05479K1060 - Common Stock - Currency: USD

1.81  +0.02 (+1.12%)

After market: 1.81 0 (0%)

Fundamental Rating

2

Overall ELUT gets a fundamental rating of 2 out of 10. We evaluated ELUT against 558 industry peers in the Biotechnology industry. ELUT may be in some trouble as it scores bad on both profitability and health. ELUT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELUT had negative earnings in the past year.
In the past year ELUT has reported a negative cash flow from operations.
ELUT had negative earnings in each of the past 5 years.
In the past 5 years ELUT always reported negative operating cash flow.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

ELUT's Return On Assets of -147.29% is on the low side compared to the rest of the industry. ELUT is outperformed by 84.95% of its industry peers.
Industry RankSector Rank
ROA -147.29%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

ELUT has a Gross Margin of 43.30%. This is in the better half of the industry: ELUT outperforms 75.27% of its industry peers.
In the last couple of years the Gross Margin of ELUT has remained more or less at the same level.
ELUT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ELUT has been increased compared to 1 year ago.
ELUT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ELUT is higher compared to a year ago.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -9.65, we must say that ELUT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.65, ELUT is doing worse than 73.30% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.65
ROIC/WACCN/A
WACC11.09%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

ELUT has a Current Ratio of 0.81. This is a bad value and indicates that ELUT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.81, ELUT is not doing good in the industry: 89.78% of the companies in the same industry are doing better.
A Quick Ratio of 0.70 indicates that ELUT may have some problems paying its short term obligations.
ELUT has a worse Quick ratio (0.70) than 90.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.7
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

5

3. Growth

3.1 Past

ELUT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.21%, which is quite impressive.
The Revenue has been growing slightly by 4.86% in the past year.
ELUT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.69% yearly.
EPS 1Y (TTM)23.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)4.86%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-9.92%

3.2 Future

Based on estimates for the next years, ELUT will show a very strong growth in Earnings Per Share. The EPS will grow by 35.00% on average per year.
ELUT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.67% yearly.
EPS Next Y73.57%
EPS Next 2Y35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.73%
Revenue Next 2Y46.67%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ELUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ELUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

ELUT's earnings are expected to grow with 35.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELUT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELUTIA INC

NASDAQ:ELUT (6/20/2025, 8:00:02 PM)

After market: 1.81 0 (0%)

1.81

+0.02 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-28 2025-07-28
Inst Owners40.91%
Inst Owner ChangeN/A
Ins Owners2.18%
Ins Owner Change3.5%
Market Cap74.43M
Analysts82.5
Price Target7.65 (322.65%)
Short Float %0.3%
Short Ratio1.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.11%
Min EPS beat(2)-1.96%
Max EPS beat(2)52.18%
EPS beat(4)2
Avg EPS beat(4)-39.76%
Min EPS beat(4)-235.71%
Max EPS beat(4)52.18%
EPS beat(8)2
Avg EPS beat(8)-49.87%
EPS beat(12)4
Avg EPS beat(12)-30.92%
EPS beat(16)5
Avg EPS beat(16)-26.09%
Revenue beat(2)0
Avg Revenue beat(2)-10.12%
Min Revenue beat(2)-11.1%
Max Revenue beat(2)-9.14%
Revenue beat(4)0
Avg Revenue beat(4)-9.88%
Min Revenue beat(4)-12.03%
Max Revenue beat(4)-7.25%
Revenue beat(8)2
Avg Revenue beat(8)-5.68%
Revenue beat(12)3
Avg Revenue beat(12)-4%
Revenue beat(16)4
Avg Revenue beat(16)-3.12%
PT rev (1m)-16.67%
PT rev (3m)-16.67%
EPS NQ rev (1m)5.56%
EPS NQ rev (3m)10.53%
EPS NY rev (1m)7.25%
EPS NY rev (3m)28.49%
Revenue NQ rev (1m)-13.82%
Revenue NQ rev (3m)-16.03%
Revenue NY rev (1m)-12.77%
Revenue NY rev (3m)-13.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.82
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.7
OCFYN/A
SpS0.74
BVpS-0.89
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.3%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.54%
Cap/Sales 3.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.7
Altman-Z -9.65
F-Score4
WACC11.09%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y73.57%
EPS Next 2Y35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.86%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-9.92%
Revenue Next Year15.73%
Revenue Next 2Y46.67%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-49.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.11%
OCF growth 3YN/A
OCF growth 5YN/A